A community 10,000-strong,

Nearly 20 years ago, Anthony met a doctor looking for investors to help launch a promising cancer therapy. That experience woke him to the immense challenge facing the mission to eliminate cancer: not funding for research, but investors willing to take significant financial risks, and possibly benefit from the rewards of supporting cancer innovations. It took losing his father to cancer, and starting his own family, to motivate Anthony to launch CANCER FUND, wanting more options and better outcomes for his own kids should they be diagnosed with cancer someday.

Anthony is the Founder of CANCER FUND and Managing Director of CANCER FUND I. He has 20+ years of experience building early-stage ventures, taking several from concept through exit. His advisory, consulting, and executive experience includes work with medical device, pharmaceutical, bioinformatics, wellness, and healthcare IT/IoT companies. Anthony earned his BS in Business Management & Entrepreneurship from DePaul University adding non-degree undergraduate and graduate studies in design, engineering, and business from ASU, Illinois Institute of Technology, and Northwestern University.

Ann is a serial entrepreneur, author, and cancer advocate. After her own cancer diagnosis in 2014, Ann, who spent several decades as a surgical assistant to a glaucoma specialist, recognized how little she knew about the cancer journey, even with her vast medical background. This raised a question in her mind: "If I found the experience difficult, what must it be like to have no medical background and receive a cancer diagnosis?" This question was the impetus for her to pen Holy Crap I Have Cancer! Now What? What to Expect When You Weren't Expecting, a book that assists patients newly diagnosed with cancer through their treatment and into survivorship.

Prior to joining CANCER FUND, Ann spent nearly a decade as the Executive Director of a Phoenix-based non-profit, Hearts of Stone, whose mission is "to develop entrepreneurism in at-risk children and to transform the organizations that support them." Ann was drawn to CANCER FUND's mission to invest in only early-stage cancer innovations and hopes to join forces with like-minded individuals driven to have a real impact on cancer. Besides her advocacy, Ann is a mom, wife, and caregiver to her elderly parents, and likes to dabble in several different mediums of art.

Jeff's personal interest in cancer took root during college when his father fell to lung cancer and was rekindled while developing and launching Athena bottled water benefiting women's cancer research. Jeff and his wife relocated to Phoenix in 2017 after fledging their youngest child and he became involved in the area's medical technology scene leading a new start-up, which eventually led him to CANCER FUND. As a CANCER FUND co-founder, Jeff wears multiple hats but professes a particular interest in engaging our stakeholders – our community, investors, and innovators.

Professionally, Jeff is a Fortune 50 executive turned entrepreneur with a passion for early-stage ventures. After 15 years holding domestic and international responsibility for some of the world's largest and most trusted consumer brands, Jeff helped launch a variety of start-ups in sectors ranging from entertainment to media to consumer products. Jeff has his MBA from the Kellogg School at Northwestern University and a BBA from Washington State University.

Prashanth recently watched a close relative suffer through cancer, seemingly beating the disease with one of the most advanced therapies in the market, only to succumb to other conditions triggered by the disease. This experience reinforced for Prashanth that, despite the tremendous progress in the fight against cancer, there is much work to be done. Prashanth was drawn to CANCER FUND's mission to bridge the funding gap for early innovators while empowering individual investors to vote with and invest their funds for impact.

Prashanth has spent the majority of his 25+ year career focused on healthcare and life sciences technology, holding product and business development executive leadership roles in Fortune 50 companies and startups. He spent the last few years in private equity in investor/operating roles including working with portfolio companies focused on leveraging oncology Real World Data in clinical development through commercialization of therapies. Prashanth is an early stage investor across multiple funds.

Prashanth earned his PhD in Electrical and Computer Engineering from the University of Cincinnati with his dissertation focused on novel skin imaging approaches for the detection and assessment of skin cancer.

Avi's journey into cancer research and impact investment has been both recent and profound. While his parents' survival stories from cancer were due to early diagnoses and effective treatments, the true impact of these experiences came to light over time.

For the past 25 years, Avi has been a dedicated professional in the healthtech industry, with a primary focus on inflammation and autoimmunity. In 2022, he ventured into new territory, advising two early-stage startups with a specific focus on oncology. However, it was a deeply personal turn of events in early 2023, when Avi became a caregiver for a close family member battling cancer, that ignited his sense of mission and purpose.

Avi is a seasoned entrepreneur, having founded biotech and clinical diagnostics companies. He earned his Ph.D. in biotechnology from Tel-Aviv University and boasts an impressive portfolio of scientific publications and patents in the field of diagnostics.

Nearly a decade ago, John lost a dear friend to breast cancer who was unaware she had it until it was 'too late', due to a lack of access to proper prevention and treatment care. It is one of the reasons he supports organizations like the Connie Dwyer Breast Center, which provides free breast care to uninsured and underserved women, and what drew him to the impact-oriented nature of Cancer Fund.

John comes from an economics and finance background, starting his career in retail real estate strategy and alternative investments before moving into venture capital. He has ten years of venture experience investing in companies from seed to D stages and advising portfolio companies post-investment. John is a native of New Jersey, but his home away from home is Italy. He received his MBA from SDA Bocconi in Milan.

Transformed by a personal tragedy in which she lost loved ones to cancer, Jennifer has dedicated two decades to guiding companies in turning cutting-edge science into life-saving treatments. As part of CANCER FUND, she contributes her expertise to their unique mission of improving patient outcomes, expanding healthcare access, and reducing care costs.

With a strong track record of expediting breakthrough therapies, Jennifer has contributed to the FDA approvals of seven novel therapies, generating $20 billion in value. An investor and STEM advocate, she focuses her investments on companies advancing science and technology for global impact.

Jennifer serves on multiple private and non-profit boards and is a published author in esteemed medical and scientific journals. She holds a bachelor's degree in Biochemistry from the University of Illinois and a master's in Regulatory Compliance from Northwestern University.

Ed has spent the past 20+ years as a cancer researcher, life sciences leader, and entrepreneur. He devoted his career to building personalized medicine technologies because each cancer is as unique as the person whose life it disrupts.

Ed is the Head of Biologics Development at Detect, Inc., a molecular diagnostics startup delivering at-home lab-quality tests. He is also Co-Founder/Chief Scientific Officer at Spin Bio, a life sciences startup building a novel single cell analysis platform. He previously co-founded several other life sciences startups and consults for, advises, and mentors other life sciences startups.

Ed received his Bachelors in Public Health and Masters in Biotechnology from Johns Hopkins University, his PhD in Molecular Medicine/Cancer Biology from the University of Maryland Baltimore, and did his Postdoctoral Fellowship at Scripps Research.

Vinona Bhatia's father fought a 14-year battle with CLL. Seeing firsthand how access to the right information, trials, and innovations can shape a patient's journey is what drives her work at Cancer Fund.

Vinona Bhatia, MD, MPH, is a hematologist-oncologist, healthcare operator, and investor with deep expertise in precision oncology, biomarker-driven care, and health equity. Following her clinical practice at UCSF and Kaiser, she spent over a decade in pharma strategy and innovation, including roles on Roche's Global Oncology team and as CMO and CEO of digital health companies. She is the Founder of P4CI (Partnering for Cancer Innovation), advising early-stage oncology companies on clinical strategy, and serves as an LP and advisor at How Women Invest and Coyote Ventures. Dr. Bhatia completed her oncology fellowship at UCSF and holds an MPH from Harvard T.H. Chan School of Public Health.